Jun 22, 2026
AbbVie (ABBV) Stock Dips as $10.9B Apogee Therapeutics Acquisition Nears Completion
AbbVie (ABBV) stock dropped 2% on a $10.9B Apogee deal. JPMorgan calls it strategic. Learn why analysts back this immunology pipeline expansion.
The post AbbVie (ABBV) Stock Dips as $10.9B Apogee Therapeutics Acquisition Nears Completion appeared first on Blockonomi.
Source: Blockonomi →Related News
- 36 minutes ago
UnitedHealth (UNH) Stock Soars 8% as Medical Cost Ratio Beats Wall Street Estima...
- 43 minutes ago
Databricks Raises $3B in Coatue-Led Round, Soars to $188B Valuation on Surging A...
- 44 minutes ago
Airbus Secures Massive $17.8B Aircraft Deal From Three Chinese Airlines
- 1 hour ago
Fifth Third Bancorp (FITB) Shares Rally on Strong Q2 Earnings Beat Driven by Com...
- 1 hour ago
AST SpaceMobile (ASTS) Stock Plunges 50% — Is Now the Time to Buy?